Patients

Bio-Path is conducting multiple clinical studies in adults with hematologic malignancies or solid tumors.

Abbreviated study descriptions are below. For more detailed inclusion and exclusion criteria and a list of sites where the study is enrolling, please visit the appropriate clinicatrials.gov listing.

Acute Myeloid Leukemia (AML)

Study stage: Phase 2

Recruiting status: open

Candidate: prexigebersen (BP1001)

Other medications: Venetoclax, Decitabine

Patient characteristics:

untreated AML patients; refractory/relapsed AML patients; venetoclax resistant or intolerant AML patients

Age: 18yr and older

Advanced or Recurrent Solid Tumors

Study stage: Phase 1

Recruiting status: not yet recruiting

Candidate: BP-1001-A

Other medications: paclitaxel

Patient characteristics:

patients with advanced or recurrent solid tumors

Age: 18yr and older

Advanced Lymphoid Malignancies

Study stage: Phase 1

Recruiting status: open

Candidate: prexigebersen-A (BP1001-A)

Other medications: none

Patient characteristics:

patients with relapsed or refractory lymphoid malignancies such as (but not limited to) mantle cell lymphoma, PTCL, follicular lymphoma, Hodgkin lymphoma and DLBCL

Age: 18yr and older

Refractory or Relapsed AML

Study stage: Phase 1

Recruiting status: not yet recruiting

Candidate: BP1002

Other medications: decitabine

Patient characteristics:

patients with refractory or relapsed AML

Age: 18yr and older